Is RLAY or ABVX more profitable?

Relay Therapeutics' return on equity of -43.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Abivax N/A -99.02% -70.26%

Does the media prefer RLAY or ABVX?

In the previous week, Abivax had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Abivax and 7 mentions for Relay Therapeutics. Abivax's average media sentiment score of 0.57 beat Relay Therapeutics' score of 0.41 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or PRAX more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media prefer RLAY or PRAX?

In the previous week, Relay Therapeutics had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Relay Therapeutics and 3 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.47 beat Relay Therapeutics' score of 0.41 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CYTK or RLAY?

In the previous week, Cytokinetics had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 12 mentions for Cytokinetics and 7 mentions for Relay Therapeutics. Cytokinetics' average media sentiment score of 1.00 beat Relay Therapeutics' score of 0.41 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KRYS or RLAY?

In the previous week, Relay Therapeutics had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Relay Therapeutics and 4 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.70 beat Relay Therapeutics' score of 0.41 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RLAY or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Nuvalent N/A -40.11% -35.43%

Does the media refer more to RLAY or NUVL?

In the previous week, Relay Therapeutics and Relay Therapeutics both had 7 articles in the media. Nuvalent's average media sentiment score of 0.43 beat Relay Therapeutics' score of 0.41 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Relay Therapeutics (RLAY) Competitors

$14.26 +0.36 (+2.55%)

As of 01:11 PM Eastern

Compare

RLAY vs. ABVX, PRAX, CYTK, KRYS, and NUVL

Should you buy Relay Therapeutics stock or one of its competitors? MarketBeat compares Relay Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relay Therapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Relay Therapeutics compare to Abivax?

Relay Therapeutics (NASDAQ:RLAY) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Relay Therapeutics currently has a consensus price target of $23.30, suggesting a potential upside of 63.45%. Abivax has a consensus price target of $137.15, suggesting a potential upside of 3.28%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Abivax had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Abivax and 7 mentions for Relay Therapeutics. Abivax's average media sentiment score of 0.57 beat Relay Therapeutics' score of 0.41 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics' return on equity of -43.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Abivax	N/A	-99.02%	-70.26%

Relay Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	177.92	-$276.48M	-$1.57	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Abivax on 12 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to Praxis Precision Medicines?

Relay Therapeutics (NASDAQ:RLAY) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Relay Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

Praxis Precision Medicines' return on equity of -43.02% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Relay Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	177.92	-$276.48M	-$1.57	N/A
Praxis Precision Medicines	$8.55M	1,125.62	-$303.27M	-$13.37	N/A

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Relay Therapeutics presently has a consensus target price of $23.30, indicating a potential upside of 63.45%. Praxis Precision Medicines has a consensus target price of $592.67, indicating a potential upside of 71.69%. Given Praxis Precision Medicines' higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Relay Therapeutics had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Relay Therapeutics and 3 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.47 beat Relay Therapeutics' score of 0.41 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Relay Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Relay Therapeutics	N/A	-43.94%	-40.11%

Relay Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	108.09	-$784.96M	-$6.84	N/A
Relay Therapeutics	$15.35M	177.92	-$276.48M	-$1.57	N/A

Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Cytokinetics presently has a consensus target price of $99.30, suggesting a potential upside of 29.84%. Relay Therapeutics has a consensus target price of $23.30, suggesting a potential upside of 63.45%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Cytokinetics had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 12 mentions for Cytokinetics and 7 mentions for Relay Therapeutics. Cytokinetics' average media sentiment score of 1.00 beat Relay Therapeutics' score of 0.41 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Relay Therapeutics beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Krystal Biotech currently has a consensus target price of $324.11, indicating a potential upside of 4.78%. Relay Therapeutics has a consensus target price of $23.30, indicating a potential upside of 63.45%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Krystal Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Relay Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Relay Therapeutics	N/A	-43.94%	-40.11%

Krystal Biotech has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	23.43	$204.83M	$7.48	41.35
Relay Therapeutics	$15.35M	177.92	-$276.48M	-$1.57	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Relay Therapeutics had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Relay Therapeutics and 4 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.70 beat Relay Therapeutics' score of 0.41 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Krystal Biotech beats Relay Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Nuvalent?

Relay Therapeutics (NASDAQ:RLAY) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Relay Therapeutics and Relay Therapeutics both had 7 articles in the media. Nuvalent's average media sentiment score of 0.43 beat Relay Therapeutics' score of 0.41 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relay Therapeutics currently has a consensus target price of $23.30, indicating a potential upside of 63.45%. Nuvalent has a consensus target price of $140.29, indicating a potential upside of 27.08%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.94

Relay Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	177.92	-$276.48M	-$1.57	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent's return on equity of -40.11% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Nuvalent	N/A	-40.11%	-35.43%

Relay Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 5.0% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Nuvalent on 9 of the 14 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.73B	$3.03B	$6.42B	$12.60B
Dividend Yield	N/A	1.97%	2.75%	5.26%
P/E Ratio	-9.08	17.52	21.28	26.32
Price / Sales	177.92	342.32	558.91	114.49
Price / Cash	N/A	56.31	43.49	56.90
Price / Book	4.26	6.22	10.60	7.34
Net Income	-$276.48M	$75.84M	$3.56B	$337.06M
7 Day Performance	5.36%	4.26%	3.21%	3.67%
1 Month Performance	13.40%	2.60%	6.51%	7.41%
1 Year Performance	362.82%	32.44%	36.74%	37.93%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	2.5626 of 5 stars	$14.26 +2.6%	$23.30 +63.5%	+371.2%	$2.73B	$15.35M	N/A	330	Analyst Forecast Analyst Revision
ABVX Abivax	2.4622 of 5 stars	$121.99 flat	$137.15 +12.4%	+2,179.9%	$9.72B	N/A	N/A	61	Earnings Report Analyst Forecast
PRAX Praxis Precision Medicines	3.1144 of 5 stars	$343.56 flat	$592.67 +72.5%	+852.3%	$9.58B	$8.55M	N/A	110	Analyst Forecast
CYTK Cytokinetics	3.2655 of 5 stars	$76.94 flat	$99.30 +29.1%	+153.7%	$9.57B	$88.04M	N/A	250	Positive News Insider Trade
KRYS Krystal Biotech	2.5898 of 5 stars	$299.45 flat	$324.11 +8.2%	+151.5%	$8.83B	$389.13M	40.03	210	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. ABVX, PRAX, CYTK, KRYS, and NUVL

How does Relay Therapeutics compare to Abivax?

Summary

How does Relay Therapeutics compare to Praxis Precision Medicines?

Summary

How does Relay Therapeutics compare to Cytokinetics?

Summary

How does Relay Therapeutics compare to Krystal Biotech?

Summary

How does Relay Therapeutics compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. ABVX, PRAX, CYTK, KRYS, and NUVL

How does Relay Therapeutics compare to Abivax?

Do analysts recommend RLAY or ABVX?

Does the media prefer RLAY or ABVX?

Is RLAY or ABVX more profitable?

Which has preferable earnings & valuation, RLAY or ABVX?

Which has more volatility & risk, RLAY or ABVX?

Do insiders and institutionals hold more shares of RLAY or ABVX?

Summary

How does Relay Therapeutics compare to Praxis Precision Medicines?

Which has more volatility and risk, RLAY or PRAX?

Is RLAY or PRAX more profitable?

Which has better earnings & valuation, RLAY or PRAX?

Do insiders & institutionals believe in RLAY or PRAX?

Do analysts prefer RLAY or PRAX?

Does the media prefer RLAY or PRAX?

Summary

How does Relay Therapeutics compare to Cytokinetics?

Is CYTK or RLAY more profitable?

Which has stronger earnings & valuation, CYTK or RLAY?

Which has more volatility and risk, CYTK or RLAY?

Do analysts rate CYTK or RLAY?

Does the media favor CYTK or RLAY?

Do institutionals & insiders have more ownership in CYTK or RLAY?

Summary

How does Relay Therapeutics compare to Krystal Biotech?

Do analysts recommend KRYS or RLAY?

Which has more volatility & risk, KRYS or RLAY?

Is KRYS or RLAY more profitable?

Which has higher earnings & valuation, KRYS or RLAY?

Do insiders and institutionals hold more shares of KRYS or RLAY?

Does the media refer more to KRYS or RLAY?

Summary

How does Relay Therapeutics compare to Nuvalent?

Does the media refer more to RLAY or NUVL?

Do analysts recommend RLAY or NUVL?

Which has stronger earnings and valuation, RLAY or NUVL?

Is RLAY or NUVL more profitable?

Which has more risk & volatility, RLAY or NUVL?

Do institutionals and insiders believe in RLAY or NUVL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools